The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. 

A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.



Understand the challenges China-based developers face when trying to get anything approved in the US
Delve into clinical trial successes and failures across a variety of tumour types
Explore Merck and others’ efforts to maintain patent exclusivity
Know what lies ahead, with the possibility of new launches in the US and EU